The use of Ingaron® in the treatment of chronic viral hepatitis B

Cover Page

Cite item

Full Text

Abstract

The possibility of antiviral therapy with the direct antiviral drugs Entecavir and Ingaron®, as an antiviral and immunomodulating therapy, was studied in patients with the recurrent chronic viral hepatitis B. The study showed the applicability of this treatment regimen, due to the increase in the number of patients with SVR, high tolerability and the absence of clinically significant side effects.

About the authors

Ekaterina A. Zaytseva

Samara State Medical University

Author for correspondence.
Email: ekasokova@mail.ru

Candidate of medical Sciences, infectious diseases doctor

Russian Federation, Samara

Larisa L. Popova

Samara State Medical University

Email: l.l.popova@samsmu.ru

Doctor of Medical Sciences, Professor of the Department of Infectious Diseases with Epidemiology

Russian Federation, Samara

Dmitry Yu. Konstantinov

Samara State Medical University

Email: d.yu.konstantinov@samsmu.ru

Doctor of Medical Sciences, Head of the Department of Infectious Diseases with Epidemiology

Russian Federation, Samara

References

  1. Global hepatitis report 2017. WHO. Geneva, 2017. 83 p.
  2. Бакулин И.Г. Хайменова Т.Ю., Сидорова И.О. Лечение больных циррозом печени HBV-этиологии: успехи, нерешенные вопросы // Терапевтический архив. – 2013. – Т.85. – № 12. – С. 114–118. [Bakulin G, Khaĭmenova TI, Sidorova IO. Treatment of patients with HBV cirrhosis: Successes, unsolved problems Therapeutic archive. 2013;85(12):114–118. (In Russ.)]
  3. Михайлов М.И., Ющук Н.Д., Малинникова Е.Ю. и др. Вирусные гепатиты – проблема общественного здоровья в Российской Федерации (проект программы по контролю и ликвидации вирусных гепатитов) // Оргздрав: Новости. Мнения. Обучение. Вестник ВШОУЗ. – 2018. – № 2(12). – С. 20–29. [Mikhaylov MI, Yushchuk ND, Malinnikova EYu, et al. Viral hepatitis as public health problem in the russian federation (a design program for the control and elimination of viral hepatitis). Healthcare management: news. views. education. bulletin of VSHOUZ. 2018;2(12):20–29. (In Russ.). https://doi.org/10.24411/2411-8621-2018-12002.
  4. Жданов К.В., Лобзин Ю.В., Гусев Д.А., Козлов К.В. Вирусные гепатиты. – СПб.: Фолиант, 2011. [Zhdanov KV, Lobzin YuV, Gusev DA, Kozlov KV. Virusnye gepatity. Saint Petersburg: Foliant; 2011. (In Russ.)]
  5. Рекомендации по диагностике и лечению взрослых больных гепатитами В и С / под ред. В.Т. Ивашкина, Н.Д. Ющука. – М.: Гэотар–Медиа, 2015. [Rekomendacii po diagnostike i lecheniyu vzroslyh bol’nyh gepatitami V i S. Ed. by V.T. Ivashkin, N.D. Yushchuk. Moscow: Geotar–Media; 2015. (In Russ.)]
  6. Мамонова Н.А., Сухарева Г.В., Чуланов В.П. и др. Эффективность энтекавира у ламивудинрефрактерных больных хроническим гепатитом В при раннем переключении с ламивудина на энтекавир: предварительный анализ результатов трехлетнего исследования // Инфекционные болезни. – 2014. – Т. 12. – № 1. – С. 81–86. [Mamonova NA, Sukhareva GV, Chulanov VP, et al. Effektivnost’ entekavira u lamivudinrefrakternyh bol’nyh hronicheskim gepatitom V pri rannem pereklyuchenii s lamivudina na entekavir: predvaritel’nyj analiz rezul’tatov trekhletnego issledovaniya. Infectious diseases. 2014;12(1):81–86. (In Russ.)]
  7. Terrault NA, Bzowej NH, Chang K-M, et al. AASLD Commission recommendations for the treatment of chronic hepatitis. Hepatologies. 2016;63(1):261–283. https://doi.org/10.1002/hep.28156.
  8. Isorce N, Testoni B, Locatelli M, et al. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Res. 2016;130:36–45. https://doi.org/10.1016/j.antiviral.2016.03.008.
  9. Deng L, Tang H. Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. Hepatol Res. 2011;41(11):1017–1024. https://doi.org/10.1111/j.1872-034X.2011.00873.x.
  10. Qi Y, Gao Z, Xu G, et al. DNA polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog. 2016;12(10):e1005893. https://doi.org/10.1371/journal.ppat.1005893.
  11. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. https://doi.org/10.1016/j.jhep. 2017.03.021.
  12. Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology. 2012;143(3):619–628. https://doi.org/10.1053/j.gastro.2012.05.037.
  13. Li L, Liu M, Cheng L-W, et al. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand J Immunol. 2013;78(5):439–446. https://doi.org/10.1111/sji.12099.
  14. Chen G-y, He J-q, Lv G-c, et al. Involvement of TRAIL up-regulation of CD4+, CD8+ T cells in liver injury in chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2004;12(5):284–286. (In Chinese)
  15. Iwamura K. Laparoscopic and histologic abnormalities of the liver in chronic asymptomatic hepatitis B surface antigen carriers. Tokai J Exp Clin Med. 1981;6(4):385–391.
  16. Lang PA, Lang KS, Xu HC, et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci USA. 2012;109(4):1210–1215. https://doi.org/10.1073/pnas.1118834109.
  17. Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013;58(6):1888–1896. https://doi.org/10.1002/hep.26549.
  18. Rivkin A. Entecavir: A new nucleosideanalogueforthe treatment of chronic hepatitis B. Drugs Today (Barc). 2007;43(4):201–220. https://doi.org/10.1358/dot.2007.43.4.1037479.
  19. Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World J Gastroenterol. 2012;18(20):2443–2451. https://doi.org/10.3748/wjg.v18.i20.2443.
  20. Tseng TC, Liu CJ, Su TH, et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis. 2012;206(10):1521–1531. https://doi.org/10.1093/infdis/jis569.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Zaytseva E.A., Popova L.L., Konstantinov D.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).